# CHROMOSOME TRANSLOCATED ONCOGENES AND NEOPLASIA

> **NIH NIH R01** · STATE UNIVERSITY NEW YORK STONY BROOK · 1988 · $248,820

## Abstract

The murine and human cellular analogues of an avian retroviral transforming
gene (c-myc) have been directly associated with chromosome translocations
commonly observed in murine plasmacytomas (t(12;15)) and Burkitt lymphomas
(t(8;14)).  We propose to continue and extend our studies of the molecular
basis and consequences of myc gene activation for cell transformation.
Different molecular targets for myc rearrangements in murine plasmacytomas
(PCTs) will be localized and their structures and significance for myc
expression determined.  To this end, we have recently identified a novel
class of PCTs with translocation breakpoints clustered 5' of c-myc which
alter the regulation of myc expression.  The site of these translocations
define the locations of putative regulatory elements important for normal
c-myc gene control.  The activities of c-myc promoter and potential
enhancer elements will be assessed by their ability to drive the expression
of a fused gene (i.e., chloramphenicol acetyl transferase or CAT) in
fibroblasts and different lymphoid cell types.  The chromatin structures of
transcriptionally active and silent c-myc alleles will be compared to
further characterize important regulatory regions.  Modified myc genes will
be stably integrated into lymphoid tumor cells which express either normal
or truncated myc RNAs.  The resultant effect(s) on normal and cryptic myc
promoter activities will be determined.  The activity of transfected and
endogenous myc genes will also be compared in these transfected cells with
myc exon and intron specific probes.  These experiments will allow us to
investigate potential cis or trans systems for regulating myc expression.
The contributions of transcriptional and post-transcriptional mechanisms
for c-myc expression will be assessed in a variety of lymphoid tumor lines
bearing translocations which disrupt the c-myc locus.  Finally, murine
retroviral vectors containing either activated myc or human ras oncogenes
will be introduced into normal proliferating B cells and their effects on
growth factor dependency analyzed.  (X)

## Key facts

- **NIH application ID:** 3173771
- **Project number:** 5R01CA036246-05
- **Recipient organization:** STATE UNIVERSITY NEW YORK STONY BROOK
- **SAM.gov UEI:** M746VC6XMNH9
- **Principal Investigator:** KENNETH B MARCU
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1988
- **Award amount:** $248,820
- **Award type:** 5
- **Project period:** 1984-07-01 → 1989-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3173771

## Citation

> US National Institutes of Health, RePORTER application 3173771, CHROMOSOME TRANSLOCATED ONCOGENES AND NEOPLASIA (5R01CA036246-05). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3173771. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*